Abeid Athman (Omar).· @bin_abeid · X·· 1 天前评分70
正文 · 原文
In patients harbouring MET mutation mNSCLC progressing on Osimertinib, the addition of savolitinib improves PFS and OS compared to the SoC. #ESMO26 @myESMO @curijoey @StephenVLiu @OncoAlert @darioT_
5 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Abeid Athman (Omar). · x.com